Role of pertuzumab in the treatment of HER2-positive breast cancer

Código QR

Role of pertuzumab in the treatment of HER2-positive breast cancer

Michael Hubalek, Christine Brantner, Christian MarthBrustgesundheitzentrum Tirol, Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, AustriaAbstract: Pertuzumab, a humanized monoclonal antibody to the HER2 receptor, represents a promising new anti-HER2 agent with a nov...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hubalek M, Brantner C, Marth C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/dc8f9d08320445b28d6baa69685854ba
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
por: Moya-Horno I, et al.
Publicado: (2015)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Jamunarani Veeraraghavan, et al.
Publicado: (2021)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
por: Jagosky M, et al.
Publicado: (2021)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra DR, et al.
Publicado: (2014)

Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
por: Hurvitz SA, et al.
Publicado: (2012)

New developments in the treatment of HER2-positive breast cancer
por: Nahta R
Publicado: (2012)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani P, et al.
Publicado: (2015)

Potential of afatinib in the treatment of patients with HER2-positive breast cancer
por: Geuna E, et al.
Publicado: (2012)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki M
Publicado: (2014)

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
por: G. Griguolo, et al.
Publicado: (2021)

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
por: Ilana Schlam, et al.
Publicado: (2021)

Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer
por: Merriam PA, et al.
Publicado: (2011)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Gaia Griguolo, et al.
Publicado: (2021)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem DD, et al.
Publicado: (2014)

De-escalation of radiation therapy in patients with stage I, node-negative, HER2-positive breast cancer
por: Jose G. Bazan, et al.
Publicado: (2021)

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data
por: Natansh D. Modi, et al.
Publicado: (2021)

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort
por: Xavier Pivot, et al.
Publicado: (2017)

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
por: Laura M. Spring, et al.
Publicado: (2021)

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
por: Hanne Vos, et al.
Publicado: (2021)

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression
por: Veronica Giusti, et al.
Publicado: (2021)

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
por: Lize Wang, et al.
Publicado: (2021)

Cancer biomarker HER-2/neu in breast cancer in Indian women
por: Singhai R, et al.
Publicado: (2011)

PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
por: Laura Pizzuti, et al.
Publicado: (2021)

Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer
por: Federica Miglietta, et al.
Publicado: (2021)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Francesco Schettini, et al.
Publicado: (2021)

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers
por: Leticia De Mattos-Arruda, et al.
Publicado: (2021)

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women
por: Vinayak W Patil, et al.
Publicado: (2011)

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer
por: Abdel Kader Y, et al.
Publicado: (2013)

Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting
por: Matthew M Seavey, et al.
Publicado: (2009)

Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates
por: Daniel Y. Joh, et al.
Publicado: (2021)

Cardiac risk in the treatment of breast cancer: assessment and management
por: Valachis A, et al.
Publicado: (2015)

Breast cancer in Brazil: epidemiology and treatment challenges
por: Cecilio AP, et al.
Publicado: (2015)

Breast cancer causes and treatment: where are we going wrong?
por: Seymour CB, et al.
Publicado: (2013)

New approaches in the management of advanced breast cancer &ndash; role of combination treatment with liposomal doxorubicin
por: Iain RJ Macpherson, et al.
Publicado: (2009)

Author Correction: Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates
por: Daniel Y. Joh, et al.
Publicado: (2021)

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
por: Brock Schroeder, et al.
Publicado: (2017)

The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study
por: Elena I. Kovalenko, et al.
Publicado: (2020)

Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer
por: Tamar Zahavi, et al.
Publicado: (2021)

The role of peroxiredoxin II in chemoresistance of breast cancer cells
por: Wang T, et al.
Publicado: (2014)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum]
por: Criscitiello C, et al.
Publicado: (2018)